Noxilizer Inc. has collected $30 million in growth capital financing from NewVale Capital to help expand its nitrogen dioxide (NO₂) sterilization platform.

The company’s sterilization method can help address an urgent market demand for alternatives to ethylene oxide (EtO); various pharmaceutical, biotechnology, and medical device companies already rely on Noxilizer to sterilize critical drug-device combination products. This growth financing will expand access to Noxilizer’s NO₂ sterilization platform to meet growing global demand.

“This investment allows us to broaden availability of NO₂ sterilization at a time when manufacturers urgently need validated, commercial-ready alternatives to existing methods,” Noxilizer President/CEO Christopher Thatcher said. “We’re proud to provide a platform that is already trusted in commercial-stage products. With NewVale Capital’s support, we are strengthening our foundation to serve our customers at scale, with long-term reliability, especially as EtO contract sterilization providers face increasing remediation mandates and capacity constraints.”

Noxilizer provides biopharmaceutical and medical device manufacturers with a commercial-grade sterilization alternative that offers:

• Commercial and Regulatory Validation: Approved by global regulatory authorities and used in marketed biopharmaceutical products
• Safety and Sustainability: Non-carcinogenic with emissions that meet room air quality standards
• Compatibility: Works with sensitive biologics, drug-device combinations, and delivery systems
• Efficiency and Scale: Provides fast cycle times, can be used in-house, and supports supply chain reliability

“Noxilizer represents one of the most viable alternatives to EtO in the market today,” NewVale Capital Founder/Managing Partner Todd Holmes stated. “The platform has already been adopted by a growing list of manufacturers, and we’re excited to support Noxilizer through its next phase of expansion to meet the rising demand for sustainable, next-generation sterilization.”

Noxilizer provides ultra-low temperature NO₂ terminal sterilization for the pharmaceutical, biotechnology, and medical device industries. With U.S. Food and Drug Administration approvals and clearance, EMA authorization, and adoption by global manufacturers, Noxilizer claims its NO₂ sterilization method is a safe, efficient, and scalable alternative to existing technologies. The company offers R&D studies, packaging and design consulting, validation, and customer and technical support in addition to its proprietary sterilization equipment and consumables. Noxilizer is headquartered in Hanover, Md.

Founded in 2021, NewVale Capital is a growth equity investment firm focused on the services architecture underpinning the life science industry. The firm invests in proven, revenue-generating services businesses across the life science ecosystem that help bring the next generation of medicines to patients.